|
1
|
Alberti KG, Eckel RH, Grundy SM, Zimmet
PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM and
Smith SC JrInternational Diabetes Federation Task Force on
Epidemiology and Prevention; National Heart, Lung and Blood
Institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; International Association
for the Study of Obesity: Harmonizing the metabolic syndrome: A
joint interim statement of the International Diabetes Federation
Task Force on Epidemiology and Prevention; National Heart, Lung and
Blood Institute; American Heart Association; World Heart
Federation; International Atherosclerosis Society; and
International Association for the Study of Obesity. Circulation.
120:1640–1645. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alberti KG, Zimmet P and Shaw JIDF
Epidemiology Task Force Consensus Group: The metabolic syndrome - a
new worldwide definition. Lancet. 366:1059–1062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Olijhoek JK, van der Graaf Y, Banga J-D,
Algra A, Rabelink TJ and Visseren FLSMART Study Group: The
metabolic syndrome is associated with advanced vascular damage in
patients with coronary heart disease, stroke, peripheral arterial
disease or abdominal aortic aneurysm. Eur Heart J. 25:342–348.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Groop L: Genetics of the metabolic
syndrome. Br J Nutr. 83 (Suppl 1):S39–S48. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park YM, Province MA, Gao X, Feitosa M, Wu
J, Ma D, Rao D and Kraja AT: Longitudinal trends in the association
of metabolic syndrome with 550 k single-nucleotide polymorphisms in
the Framingham Heart Study. BMC Proc. 3 (Suppl 7):S1162009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeggini E, Scott LJ, Saxena R, Voight BF,
Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen
G, et al Wellcome Trust Case Control Consortium: Meta-analysis of
genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes. Nat Genet.
40:638–645. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kooner JS, Chambers JC, Aguilar-Salinas
CA, Hinds DA, Hyde CL, Warnes GR, Gómez Pérez FJ, Frazer KA,
Elliott P, Scott J, et al: Genome-wide scan identifies variation in
MLXIPL associated with plasma triglycerides. Nat Genet. 40:149–151.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frayling TM, Timpson NJ, Weedon MN,
Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H,
Rayner NW, et al: A common variant in the FTO gene is associated
with body mass index and predisposes to childhood and adult
obesity. Science. 316:889–894. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schunkert H, König IR, Kathiresan S,
Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M,
Gieger C, et al Cardiogenics; CARDIoGRAM Consortium: Large-scale
association analysis identifies 13 new susceptibility loci for
coronary artery disease. Nat Genet. 43:333–338. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deloukas P, Kanoni S, Willenborg C,
Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D,
Erdmann J, Goldstein BA, et al CARDIoGRAMplusC4D Consortium;
DIAGRAM Consortium; CARDIOGENICS Consortium; MuTHER Consortium;
Wellcome Trust Case Control Consortium: Large-scale association
analysis identifies new risk loci for coronary artery disease. Nat
Genet. 45:25–33. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sattar N, Gaw A, Scherbakova O, Ford I,
O'Reilly DS, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe
SM, et al: Metabolic syndrome with and without C-reactive protein
as a predictor of coronary heart disease and diabetes in the West
of Scotland Coronary Prevention Study. Circulation. 108:414–419.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ridker PM, Buring JE, Cook NR and Rifai N:
C-reactive protein, the metabolic syndrome, and risk of incident
cardiovascular events: An 8-year follow-up of 14,719 initially
healthy American women. Circulation. 107:391–397. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanazawa M, Yoshiike N, Osaka T, Numba Y,
Zimmet P and Inoue S: Criteria and classification of obesity in
Japan and Asia-Oceania. Asia Pac J Clin Nutr. 11 (Suppl
8):S732–S737. 2002. View Article : Google Scholar
|
|
14
|
Matsuoka R, Abe S, Tokoro F, Arai M, Noda
T, Watanabe S, Horibe H, Fujimaki T, Oguri M, Kato K, et al:
Association of six genetic variants with myocardial infarction. Int
J Mol Med. 35:1451–1459. 2015.PubMed/NCBI
|
|
15
|
Yamada Y, Fuku N, Tanaka M, Aoyagi Y,
Sawabe M, Metoki N, Yoshida H, Satoh K, Kato K, Watanabe S, et al:
Identification of CELSR1 as a susceptibility gene for ischemic
stroke in Japanese individuals by a genome-wide association study.
Atherosclerosis. 207:144–149. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamada Y, Nishida T, Ichihara S, Sawabe M,
Fuku N, Nishigaki Y, Aoyagi Y, Tanaka M, Fujiwara Y, Yoshida H, et
al: Association of a polymorphism of BTN2A1 with myocardial
infarction in East Asian populations. Atherosclerosis. 215:145–152.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamada Y, Nishida T, Ichihara S, Kato K,
Fujimaki T, Oguri M, Horibe H, Yoshida T, Watanabe S, Satoh K, et
al: Identification of chromosome 3q28 and ALPK1 as susceptibility
loci for chronic kidney disease in Japanese individuals by a
genome-wide association study. J Med Genet. 50:410–418. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Itoh Y, Mizuki N, Shimada T, Azuma F,
Itakura M, Kashiwase K, Kikkawa E, Kulski JK, Satake M and Inoko H:
High-throughput DNA typing of HLA-A, -B, -C and -DRB1 loci by a
PCR-SSOP-Luminex method in the Japanese population. Immunogenetics.
57:717–729. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Remacle AG, Shiryaev SA, Oh ES, Cieplak P,
Srinivasan A, Wei G, Liddington RC, Ratnikov BI, Parent A,
Desjardins R, et al: Substrate cleavage analysis of furin and
related proprotein convertases. A comparative study. J Biol Chem.
283:20897–20906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blanchette F, Day R, Dong W, Laprise MH
and Dubois CM: TGFbeta1 regulates gene expression of its own
converting enzyme furin. J Clin Invest. 99:1974–1983. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pesu M, Muul L, Kanno Y and O'Shea JJ:
Proprotein convertase furin is preferentially expressed in T helper
1 cells and regulates interferon gamma. Blood. 108:983–985. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Turpeinen H, Raitoharju E, Oksanen A,
Oksala N, Levula M, Lyytikäinen LP, Järvinen O, Creemers JW,
Kähönen M, Laaksonen R, et al: Proprotein convertases in human
atherosclerotic plaques: The overexpression of FURIN and its
substrate cytokines BAFF and APRIL. Atherosclerosis. 219:799–806.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Turpeinen H, Ortutay Z and Pesu M:
Genetics of the first seven proprotein convertase enzymes in health
and disease. Curr Genomics. 14:453–467. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bassi DE, Mahloogi H, Al-Saleem L, Lopez
De Cicco R, Ridge JA and Klein-Szanto AJ: Elevated furin expression
in aggressive human head and neck tumors and tumor cell lines. Mol
Carcinog. 31:224–232. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ornatowski W, Poschet JF, Perkett E,
Taylor-Cousar JL and Deretic V: Elevated furin levels in human
cystic fibrosis cells result in hypersusceptibility to exotoxin
A-induced cytotoxicity. J Clin Invest. 117:3489–3497. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cousin C, Bracquart D, Contrepas A, Corvol
P, Muller L and Nguyen G: Soluble form of the (pro)renin receptor
generated by intracellular cleavage by furin is secreted in plasma.
Hypertension. 53:1077–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ehret GB, Munroe PB, Rice KM, Bochud M,
Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ,
et al CHARGE-HF consortium: Genetic variants in novel pathways
influence blood pressure and cardiovascular disease risk. Nature.
478:103–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li N, Luo W, Juhong Z, Yang J, Wang H,
Zhou L and Chang J: Associations between genetic variations in the
FURIN gene and hypertension. BMC Med Genet. 11:1242010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ganesh SK, Tragante V, Guo W, Guo Y,
Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert
J, et al CARDIOGRAM, METASTROKE; LifeLines Cohort Study: Loci
influencing blood pressure identified using a cardiovascular
gene-centric array. Hum Mol Genet. 22:1663–1678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seidah NG, Khatib AM and Prat A: The
proprotein convertases and their implication in sterol and/or lipid
metabolism. Biol Chem. 387:871–877. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Choi S and Korstanje R: Proprotein
convertases in high-density lipoprotein metabolism. Biomark Res.
1:272013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Franssen R, Visser ME, Kuivenhoven JA, et
al: Role of lipoprotein lipase in triglyceride metabolism:
Potential therapeutic target. Future Lipidol. 3:385–397. 2008.
View Article : Google Scholar
|
|
33
|
Galcheva-Gargova Z, Gangwani L,
Konstantinov KN, Mikrut M, Theroux SJ, Enoch T and Davis RJ: The
cytoplasmic zinc finger protein ZPR1 accumulates in the nucleolus
of proliferating cells. Mol Biol Cell. 9:2963–2971. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galcheva-Gargova Z, Konstantinov KN, Wu
IH, Klier FG, Barrett T and Davis RJ: Binding of zinc finger
protein ZPR1 to the epidermal growth factor receptor. Science.
272:1797–1802. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gangwani L: Deficiency of the zinc finger
protein ZPR1 causes defects in transcription and cell cycle
progression. J Biol Chem. 281:40330–40340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ahmad S, Wang Y, Shaik GM, Burghes AH and
Gangwani L: The zinc finger protein ZPR1 is a potential modifier of
spinal muscular atrophy. Hum Mol Genet. 21:2745–2758. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mangelsdorf DJ, Thummel C, Beato M,
Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M,
Chambon P, et al: The nuclear receptor superfamily: The second
decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Corton JC, Anderson SP and Stauber A:
Central role of peroxisome proliferator-activated receptors in the
actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol.
40:491–518. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sladek FM, Zhong WM, Lai E and Darnell JE
Jr: Liver-enriched transcription factor HNF-4 is a novel member of
the steroid hormone receptor superfamily. Genes Dev. 4((12B)):
2353–2365. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Waterworth DM, Ricketts SL, Song K, Chen
L, Zhao JH, Ripatti S, Aulchenko YS, Zhang W, Yuan X, Lim N, et al
Wellcome Trust Case Control Consortium: Genetic variants
influencing circulating lipid levels and risk of coronary artery
disease. Arterioscler Thromb Vasc Biol. 30:2264–2276. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Teslovich TM, Musunuru K, Smith AV,
Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S,
Chasman DI, Willer CJ, et al: Biological, clinical and population
relevance of 95 loci for blood lipids. Nature. 466:707–713. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nakayama K, Yanagisawa Y, Ogawa A,
Ishizuka Y, Munkhtulga L, Charupoonphol P, Supannnatas S, Kuartei
S, Chimedregzen U, Koda Y, et al: High prevalence of an
anti-hypertriglyceridemic variant of the MLXIPL gene in Central
Asia. J Hum Genet. 56:828–833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kathiresan S, Willer CJ, Peloso GM,
Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y,
Tanaka T, et al: Common variants at 30 loci contribute to polygenic
dyslipidemia. Nat Genet. 41:56–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Abe S, Tokoro F, Matsuoka R, et al:
Association of genetic variants with dyslipidemia. Mol Med Rep. (In
press).
|
|
45
|
Kathiresan S, Melander O, Guiducci C,
Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF,
Havulinna AS, et al: Six new loci associated with blood low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol or
triglycerides in humans. Nat Genet. 40:189–197. 2008. View Article : Google Scholar
|
|
46
|
Willer CJ, Sanna S, Jackson AU, Scuteri A,
Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS,
Stringham HM, et al: Newly identified loci that influence lipid
concentrations and risk of coronary artery disease. Nat Genet.
40:161–169. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yan SK, Cheng XQ, Song YH, Xiao XH, Bi N
and Chen BS: Apolipoprotein A5 gene polymorphism −1131T→C:
Association with plasma lipids and type 2 diabetes mellitus with
coronary heart disease in Chinese. Clin Chem Lab Med. 43:607–612.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Klos KL, Sing CF, Boerwinkle E, Hamon SC,
Rea TJ, Clark A, Fornage M and Hixson JE: Consistent effects of
genes involved in reverse cholesterol transport on plasma lipid and
apolipoprotein levels in CARDIA participants. Arterioscler Thromb
Vasc Biol. 26:1828–1836. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ken-Dror G, Goldbourt U and Dankner R:
Different effects of apolipoprotein A5 SNPs and haplotypes on
triglyceride concentration in three ethnic origins. J Hum Genet.
55:300–307. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jakel H, Nowak M, Helleboid-Chapman A,
Fruchart-Najib J and Fruchart JC: Is apolipoprotein A5 a novel
regulator of triglyceride-rich lipoproteins? Ann Med. 38:2–10.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Garelnabi M, Lor K, Jin J, Chai F and
Santanam N: The paradox of ApoA5 modulation of triglycerides:
Evidence from clinical and basic research. Clin Biochem. 46:12–19.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
O'Brien PJ, Alborn WE, Sloan JH, Ulmer M,
Boodhoo A, Knierman MD, Schultze AE and Konrad RJ: The novel
apolipoprotein A5 is present in human serum, is associated with
VLDL, HDL and chylomicrons, and circulates at very low
concentrations compared with other apolipoproteins. Clin Chem.
51:351–359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bernstein RM, Davis BM, Olefsky JM and
Reaven GM: Hepatic insulin responsiveness in patients with
endogenous hypertriglyceridaemia. Diabetologia. 14:249–253. 1978.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Talmud PJ, Cooper JA, Hattori H, Miller
IP, Miller GJ and Humphries SE: The apolipoprotein A-V genotype and
plasma apolipoprotein A-V and triglyceride levels: Prospective risk
of type 2 diabetes. Results from the Northwick Park Heart Study II.
Diabetologia. 49:2337–2340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sóter MO, Gomes KB, Fernandes AP, Carvalho
M, Pinheiro PS, Bosco AA, Silva DD and Sousa MO: −1131T>C and
SW19 polymorphisms in APOA5 gene and lipid levels in type 2
diabetic patients. Mol Biol Rep. 39:7541–7548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tokoro F, Matsuoka R, Abe S, Arai M, Noda
T, Watanabe S, Horibe H, Fujimaki T, Oguri M, Kato K, et al:
Association of a genetic variant of the ZPR1 zinc finger gene with
type 2 diabetes mellitus. Biomed Rep. 3:88–92. 2015.PubMed/NCBI
|
